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Background: This retrospective chart review investigated differences in the prevalence of medi-
cal comorbidity between women with fibromyalgia (FM) (n=219) and a control group women 
with chronic pain (CP) without FM (n=116). The specific aims were to compare the prevalence 
of autoimmune, psychiatric, endocrine, gynecologic pathology, the relationship between tim-
ing of gynecologic surgery, and pain onset. We additionally sought to compare the number of 
comorbidities in an ethnically diverse cohort.
Methods: This was a retrospective chart review of patients seen in FM or CP clinics at an 
academic medical center in 2009–2010.
Results: Logistic regression modeling found that gynecologic, endocrine, and autoimmune 
diagnoses were independently associated with a diagnosis of FM. Detailed analyses showed that 
thyroid disease (P,0.01) and gynecologic surgery (P,0.05) were significantly more common in 
FM. Women with FM were more likely to have multiple autoimmune, endocrine, gynecologic, or 
psychiatric pathologies. A relationship was observed between the timing of gynecologic surgery 
and pain onset in FM, with more surgeries observed in the years just prior to pain onset or in 
the year after pain onset. A similar pattern was not found in the control group.
Conclusion: This study demonstrates that autoimmune, endocrine, and gynecologic patholo-
gies occur more commonly in women with FM than in those with CP, which is consistent with 
findings in less ethnically diverse samples. Moreover, a relationship was found between timing 
of pain onset and gynecologic surgery. A larger prospective study of the relationship between 
gynecologic surgery and pain onset in FM is warranted.
Keywords: fibromyalgia, sex hormones, thyroid, autoimmune, chronic pain
Introduction
Fibromyalgia (FM) has a total prevalence of 2% in the general population and is dis-
proportionately more common in women after the age of 50 years, with a female to 
male ratio of 7:1.1 In women, the prevalence of FM is only 0.9% between the ages of 
18 and 30 years, but increases sharply at the age of 40–60 years, 1 a period known for 
hormonal changes in women. A higher prevalence of pain in women compared with 
men is commonly reported across a number of pain conditions, including irritable 
bowel syndrome,2,3 temporomandibular disorder,4,5 chronic musculoskeletal pain,6 
and migraines.7 FM has been demonstrated to have a higher degree of comorbidity 
with multiple conditions, including endocrine and genitourinary disorders, than in 
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 osteoarthritis and other rheumatologic conditions.8,9 FM 
frequently accompanies autoimmune disorders10,11 which 
also typically occur more commonly in women.
Several studies have assessed the presence of autoim-
mune disease in patients with FM and vice versa. There is 
an increase in autoimmune thyroid disease and autoantibody 
profile in FM patients,12 which has been proposed as a pos-
sible predisposing factor in the development of FM.13 The 
clinical severity of FM is more severe in patients with posi-
tive thyroid antibodies, and post-menopausal FM patients 
have a higher prevalence of thyroid antibodies than their 
premenopausal counterparts.11 Elevated thyroid antibodies 
are similarly seen in rheumatoid arthritis patients, which are 
also significantly greater than in healthy controls,14 though 
some studies indicate a greater frequency of antibodies in 
rheumatoid arthritis patients than FM patients.15 There is 
additionally an increased prevalence of FM in systemic 
lupus erythematosus (SLE) patients and Sjogren patients, 
with one study demonstrating FM in 32% of SLE patients 
and 18% of Sjogren patients.16 FM is associated with worse 
health status and an increase in psychiatric symptoms in SLE 
patients.17 Interestingly, when analyzing the converse, there 
appears to be no increase in the risk of developing SLE in 
patients previously diagnosed with FM.13 Yet, there is a higher 
prevalence of Raynaud’s phenomenon, sicca symptoms, and 
autoantibodies in FM patients.18
The sex differences in the prevalence of chronic pain (CP) 
conditions have generated multiple review articles about the role 
of sex hormones in pain onset, maintenance, or inhibitory con-
trol.19–24 Though substantial evidence links gonadal hormones 
and pain, the relationship between gonadal hormones and pain 
is not fully understood. One study showed that estrogen may 
have pronociceptive or antinociceptive effects depending on the 
receptor.25 Sex steroids alter levels of neuromodulators involved 
in spinal nociceptive processing, including substance P, amino 
acids such as gamma aminobutyric acid, and glutamate and have 
been shown to increase the number of excitatory synapses in 
neurons in the cortex, cerebellum, and hippocampus.24 Several 
studies have examined the relationship of gynecologic pathology 
to FM. Some (but not all) studies have shown fluctuations in 
pain levels depending on the menstrual cycle phase.20,26,27 Hys-
terectomies and early menopause additionally occur more com-
monly in FM patients than in rheumatoid arthritis controls.28,29 
Interestingly, Warren et al have noted an increased frequency of 
hysterectomies in patients developing bladder pain syndrome,30 
an entity associated with the incidence of FM.31 Further, women 
with FM who had a hysterectomy with or without oophorectomy 
were recently shown to have worse symptom severity than those 
without hysterectomy.32 In an additional study of female FM 
patients, not only was there a greater frequency of women who 
had received a hysterectomy versus those who had not, but 90% 
of the FM patients with hysterectomies reported receiving the 
surgery before the onset of FM.33 Having FM with a previous 
history of a hysterectomy was associated with a lower general 
health status.32
In addition to sex hormones, research has implicated 
other endocrine pathologies, such as those involving the 
the hypothalamic–pituitary–adrenal (HPA) axis34–37 and 
thyroid8,9,11,38–41 in FM. Research on the HPA axis in FM 
has shown variations in cortisol levels,42,43 increased sensi-
tivity to glucocorticoid feedback,44 and increased cortisol 
release in response to a stressor.45 However, other studies 
have failed to find evidence of cortisol dysregulation in 
FM.36 Following a 3-week, multidisciplinary, FM treatment 
program, improvements were noted in the function of HPA 
axis, specifically cortisol and corticoid receptor levels.46 
Altogether, the literature suggests that cortisol release may 
be abnormal in FM, but the nature of the pathology remains 
poorly understood at present.
In light of these previous studies, we sought to confirm 
these findings in our cohort of female patients, analyzing 
whether patients with FM had more autoimmune, endo-
crine, or gynecologic pathology than women of similar age 
with CP of a similar duration. As recent studies of medical 
comorbidities and FM included ethnically homogenous popu-
lations, with 97.4% of patients being non-Hispanic White, 
we sought to confirm these findings in a more ethnically 
diverse population.8,9 Specifically, this FM cohort is 53.8% 
Hispanic. We additionally sought to provide more detailed 
information on specific diagnoses and procedures, such as 
hysterectomies and oophorectomies, than previous studies on 
medical comorbidities in FM.8,9 We examined the relationship 
between onset of pain and the onset of other disorders. This 
was accomplished by looking at the timing of pain onset 
and date of hysterectomy or oophorectomy. In addition to 
endocrine and gynecologic variables, we also measured the 
prevalence of other disorders frequently comorbid with FM, 
such as psychiatric illness, chronic fatigue syndrome, and 
irritable bowel syndrome.
Materials and methods
screening
We screened all patients seen in 2009–2010 in a specialty FM 
clinic and in a CP management clinic at an academic medical 
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center for inclusion in the study. All patients who saw either 
of the two physicians in the FM clinic or general CP clinic 
were screened electronically. Patients were excluded if they 
were men or had a cancer-related pain condition as their 
primary diagnosis. A second group of patients was excluded 
if they had pain for less than 6 months, a myofascial pain 
component without an FM diagnosis, or a medical record 
with insufficient documentation regarding pain diagnosis. 
Myofascial pain was used as an exclusion criterion due to 
concern over overlap with FM. The most common diag-
noses among patients with CP included osteoarthritis and 
lower back pain. These patients did not meet the criteria for 
FM. A diagnosis of FM was made based on the previously 
published American College of Rheumatology 1990 criteria 
which includes the use of tender points.47 Approval to conduct 
this study was granted by the institutional review board of 
the University of Miami. A waiver of informed consent was 
granted for this retrospective chart review.
chart review
Charts were reviewed by the principal author (LB) and 
three medical residents. All charts reviewed by the residents 
were reviewed at least twice, and inconsistencies between 
reviewers were identified and resolved by re-reviewing 
the charts. Ten percent of the charts reviewed by LB and 
by a resident were assessed for interrater reliability, which 
exceeded 90%.
For each participant, data were gathered on diagnosis, 
year of pain onset, medical comorbidities, psychiatric 
comorbidities, surgical history, and date of hysterectomy, 
oophorectomy, or cystectomy. In addition to obtaining 
information from the physician’s notes, information on 
specific aspects of the medical history (previous surger-
ies, dates of surgeries, date of pain onset, and psychiatric 
diagnoses) from self-report medical history questionnaires 
was used when available. The diagnosis of FM was based 
on the physician note, while self-report medical history 
questionnaires and registration papers used for patients 
enrolling in the clinic, provided additional past medical 
history or clarifications of the physician note. The most dif-
ficult information to collect was the date of pain onset and 
dates of surgical procedures due to a lack of documentation. 
There was a special issue with the psychiatric data, as there 
were concerns that it was assessed with greater frequency 
as a matter of clinical practice in the FM clinic. Due to 
concerns over potential bias regarding the psychiatric data, 
all analyses in this study were run with and without the 
psychiatric data included. Though data were collected on 
most medical comorbidities, the focus of data collection 
was on endocrine, autoimmune, gynecologic, and psychi-
atric diagnoses. Grouping of diagnoses into variables is 
delineated in Table 1. Gynecologic surgeries potentially 
involving the ovaries were analyzed individually and col-
lectively to account for heterogeneity of documentation 
(eg, hysterectomy, hysterectomy + oophorectomy, and 
hysterectomy + oophorectomy + cystectomy). This analysis 
additionally allowed for a progressively more inclusive 
method for identifying gynecologic procedures, with hys-
terectomy + oophorectomy + cystectomy being the most 
inclusive cohort.
Data were also collected on hypertension, cholecystec-
tomy, and conditions frequently comorbid with FM, such 
Table 1 Diseases included in each pathology grouping
Variable Chart diagnoses included
autoimmune systemic lupus erythematosus, Rheumatoid arthritis,  
sjogren’s syndrome, Multiple sclerosis, cResT, 
Polymyalgia rheumatica
scleroderma, idiopathic thrombocytopenic purpura, 
Ulcerative colitis, sarcoidosis, psoriasis, Pernicious 
anemia
Total thyroid hashimoto’s disease, hypothyroidism, grave’s disease,  
hyperthyroidism
goiter, Thyroid nodule, Thyroidectomy
Total psychiatric Depression, anxiety schizoaffective disorder, schizophrenia
Total endocrine Pituitary microadenoma, hypopituitarism, adrenalectomy, 
Adrenal insufficiency, Parathyroidectomy
Parathyroid adenoma, Pineal tumor, neuroendocrine 
tumor
Total gynecologic hysterectomy, Oophorectomy, endometriosis, 
endometrial hyperplasia, Polycystic ovarian syndrome, 
Uterine fibroid, Fibroid removal, Ovarian cyst rupture
Ovarian cystectomy, Myomectomy, Uterotomy, 
endometrial ablation, cervical polyp removal, 
Uterine cancer, Uterine rupture
gynecologic surgery hysterectomy, Oophorectomy, Fibroid removal, 
Ovarian cystectomy, Myomectomy
Uterotomy, endometrial ablation, cervical polyp removal
Abbreviations: cResT, calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.
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as chronic fatigue syndrome and irritable bowel syndrome. 
Hypertension and cholecystectomy were selected because 
they are commonly occurring conditions and were mostly 
unrelated to the hypothesized relationships in the study, and 
thus serve as a form of control variable to assess whether 
or not patients with FM had more of all diagnoses or if the 
increased diagnostic burden was specific to the hypothesized 
conditions.
statistical analyses
All statistical analyses in the study were made using Statis-
tical Package for the Social Sciences for Windows version 
19.0 software (IBM Corporation, Armonk, NY, USA). Two 
logistic regression analyses were run. The first logistic regres-
sion model included three binary, categorical, predictor vari-
ables: history of autoimmune disorder, history of endocrine 
disorder, and history of gynecologic disorder of surgery. The 
second model included these three variables plus a history of 
psychiatric disorder. All variables were included in a single 
block with forced entry into the model.
In essence, the logistic regression analyses served as 
omnibus tests to determine if autoimmune, endocrine, 
gynecologic, and psychiatric disorders were independently 
associated with the diagnosis of FM. Chi-square analyses 
were used to look with more detail at the difference in preva-
lence of disease pathology across groups. The significance 
of these tests was defined as P#0.05 for a priori tests and as 
P#0.01 for post hoc tests to correct for multiple comparisons. 
The relationship between the timing of pain onset and the 
timing of hysterectomy/oophorectomy was analyzed for the 
subset of patients for whom such data were available (n=93). 
Additionally, Mann–Whitney U tests were used to assess 
if there were differences in the amount of comorbidities 
between FM and CP participants.
Results
A total of 335 female patients were included in the study, with 
219 in the FM group and 116 in the CP group. After exclud-
ing the nine patients who were not categorized as Caucasian, 
African-American, or Hispanic, analyses revealed significant 
differences in the ethnic composition of the FM and CP 
groups (χ2=17.6; P,0.001). The percentage of Caucasian 
patients as a total of the FM and CP groups was consistent 
(34.2% versus 34.9%, respectively). However, a larger per-
centage of Hispanics were in the FM group than in the CP 
group (53.8% versus 36.8%, respectively). In contrast, more 
African-Americans were members of the CP group than of 
the FM group (28.9% versus 11.3%, respectively). The mean 
(standard deviation) age for the FM group was 52.66 (12.3) 
and that of the CP group was 52.5 (13.3). No differences 
between groups were found by age (P=0.88) or years since 
pain onset (P=0.55).
logistic regression modeling
In the first logistic regression model, all three variables 
(autoimmune, total endocrine, total gynecologic) were 
significantly associated with the FM diagnosis (Table 2). 
When psychiatric history was included in the model, a his-
tory of autoimmune or endocrine disorders continued to be 
independently associated with a diagnosis of FM; however, 
a history of a gynecologic disorder or surgery did not remain 
significant.
Medical comorbidities
Autoimmune disorders, hypothyroidism, total thyroid, total 
endocrine, total gynecologic, depression, and total diseases 
included in each pathology grouping were significantly more 
frequent in the FM group. No differences in diabetes and 
hypertension were found between groups. Chronic fatigue 
syndrome and irritable bowel syndrome were more common 
in the FM than in the CP group. Exact proportions and gross 
P-values are listed in Table 3.
surgical history and relationship of 
hysterectomy/oophorectomy with pain 
onset
In terms of surgical history, hysterectomy + oophorectomy, 
hysterectomy + oophorectomy + cystectomy, and total 
gynecologic surgeries occurred more frequently in the FM 
group. Across all participants with a history of hysterec-
tomy or oophorectomy, the procedure preceded pain onset 
in 73.1% of cases. On average, surgery occurred 8.3 (12.8) 
years before pain onset. The range was from surgery occur-
ring 43 years before pain onset to surgery occurring 19 years 
Table 2 Logistic models predicting a diagnosis of fibromyalgia
β OR (95% CI) P-value
Model 1
autoimmune 0.83 2.29 (1.12–4.70) 0.02
Total endocrine 0.82 2.27 (1.26–4.10) 0.007
Total gynecologic 0.48 1.62 (1.02–1.59) 0.04
Model 2
autoimmune 1.10 3.01 (1.40–6.43) 0.005
Total endocrine 0.79 2.21 (1.19–4.11) 0.01
Total gynecologic 0.28 1.32 (0.80–2.19) 0.27
Total psychiatric 1.49 4.45 (2.69–7.35) 0.001
Abbreviations: CI, confidence interval; OR, odds ratio.
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after pain onset. When the distributions between FM and CP 
groups are displayed, there is a noticeable difference in the 
shape of the distributions (Figures 1 and 2). Of note, 25 and 
12 patients were excluded from the FM group and control 
group, respectively, as the time of hysterectomy was not 
available in the medical records.
In the FM group, the peak of the distribution occurs 
with surgeries occurring in the 4 (mean 7.7, median 3.5) 
years just before pain onset or in the year after pain onset 
(Figure 1). That perioperative time period accounts for 47.1% 
of the hysterectomies and oophorectomies in FM patients. 
In contrast, the same period accounts for 24.0% of surger-
ies in CP patients (mean 9.1, median 12 years). In contrast 
with the FM patients, the distribution of the timing between 
pain onset and time of surgery in CP patients appears to be 
more random.
aggregates across domains
Aggregates for each participant were calculated for endo-
crine, gynecologic, and autoimmune disorders. Data were 
coded in a binary fashion for each type of disorder (endo-
crine, gynecologic, and autoimmune) for this analysis. The 
maximum potential score was 3. For instance, if a participant 
had an autoimmune diagnosis and an endocrine diagnosis, 
then the subject would receive a score of 2. An individual 
with two endocrine diagnoses would only receive a score 
of 1. An additional set of analyses was conducted including 
endocrine, gynecologic, and autoimmune plus psychiatric 
diagnosis. Mann–Whitney U tests showed significant differ-
ences between the FM and CP groups, both when the analyses 
included only endocrine, gynecologic, and autoimmune 
diagnoses (U=9,339; P,0.001) and also when psychiatric 
diagnoses were included (U=7,556; P,0.001). Individuals in 
the FM group were 2.4 times more likely to have more than 
one endocrine, gynecologic, or autoimmune diagnosis (see 
Figure 3). When including psychiatric diagnoses, individuals 
in the FM group were 4.0 times more likely to have three or 
more diagnoses (Figure 4).
Table 3 Proportion of patients with comorbidities by group
Fibromyalgia 
(n=219)
Chronic pain 
(n=116)
Endocrine and autoimmune comorbidities
autoimmune disorders 19.2% 9.5%*
endocrine + thyroid + diabetes 44.7% 34.6%*
 Diabetes 24.2% 19.8%
 any thyroid 27.4% 14.7%**
  hypothyroid 21.5% 11.2%*
  Thyroidectomy 4.6% 1.7%
 endocrine + thyroid 30.1% 15.5%**
 endocrine (no thyroid) 4.1% 1.7%
Gynecologic comorbidities
any gynecologic surgery or  
illness
54.8% 39.7%**
any gynecologic surgery 51.6% 38.8%*
hysterectomy 39.3% 30.2%
hysterectomy/oophorectomy 43.4% 30.2%*
hysterectomy/oophorectomy/
cystectomy
45.7% 31.9%*
Other comorbidities
hypertension 45.7% 42.2%
cholecystectomy 17.8% 16.4%
irritable bowel syndrome 9.6% 0.9%**
chronic fatigue syndrome 5.5% 0.0%**
Psychiatric comorbidities
Depression + severe mental  
illness
71.7% 37.1%**
Depression 66.2% 35.3%**
Notes: *P#0.05; **P#0.01.
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Figure 1 Hysterectomy/oophorectomy and pain onset in fibromyalgia (n=68).
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Discussion
This study confirmed previous findings that autoimmune, 
gynecologic, endocrine, and total medical comorbidities are 
elevated in women with FM, even in an ethnically diverse 
cohort. We additionally demonstrate that there may be a tem-
poral relationship between pain onset and timing of hysterec-
tomy/oophorectomy. Further, we found that carrying multiple 
diagnoses was more common in the FM group than in the 
control group. As our control group consisted of women of a 
similar age with CP for a similar amount of time, differences 
between the groups may be inferred to be disease-related and 
not age-related or pain-related. Our control cohort consisted 
of CP patients, a majority of whom had lower back pain and/
or osteoarthritis, as opposed to rheumatoid arthritis patients 
as in previous studies. Given the potentially important role 
of autoimmunity in the pathogenesis of FM,48 a CP cohort 
likely serves as a more meaningful control than a rheumatoid 
arthritis control group.
Our results regarding the increased prevalence of gyne-
cologic, endocrine, and psychiatric disorders were remark-
ably similar to the findings of disease prevalence reported 
by Wolfe et al.9 This similarity in prevalence is more 
noteworthy given the demographic differences in ethnicity 
between the two study populations, thereby increasing the 
generalizability of these findings. Altogether, the data suggest 
that our study’s findings of increased endocrine, autoim-
mune, gynecologic, and psychiatric comorbidities in FM are 
specific and not due to age, ethnicity, or an increase in all 
diagnoses or procedures. The finding that hysterectomies are 
more common in women with FM has been demonstrated 
previously.28,29 Likewise, hysterectomies were related to 
greater symptom severity.32
Hysterectomies are the second most common surgery 
among reproductive-aged women,49 with more than one-
third of US women having had a hysterectomy by the age 
of 60 years.50 Therefore, if hysterectomies are a contributor 
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Figure 2 hysterectomy/oophorectomy and pain onset in chronic pain (n=25).
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Figure 4 number of comorbid endocrine, gynecologic, autoimmune, and psychiatric 
conditions.
Abbreviations: cP, chronic pain; FM, fibromyalgia.
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Figure 3 number of comorbid endocrine, gynecologic, and autoimmune 
conditions.
Abbreviations: cP, chronic pain; FM, fibromyalgia.
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to the development of FM, then why is the prevalence of 
FM so much lower than the prevalence of hysterectomies? 
Though genetic differences or pre-disease environmental 
factors likely play a role in who develops FM, one possible 
answer to the question of who develops FM is supported by 
the cumulative burden data. The data show that the presence 
of only one autoimmune, endocrine, or gynecologic condi-
tion is no more common in FM than in the CP control group; 
however, participants who had more than one condition were 
significantly more likely to have FM. This finding is even 
more pronounced when the psychiatric data are included 
as well.
An alternative explanation for our study findings is 
that a common cause is responsible for the increase in 
autoimmune, gynecologic, endocrine, and psychiatric 
comorbidities. For instance, dysfunction at the level of 
the hypothalamus or the pituitary could be responsible 
for most of those disorders. Previous review articles have 
documented that hypothalamic-pituitary dysfunction is 
implicated in gynecologic51,52 and psychiatric disorders,53,54 
while there additionally appears to be HPA axis abnormali-
ties in autoimmune disease.55,56 By definition, dysfunction 
at the level of the hypothalamus or the pituitary involves 
endocrine pathology. Central pathology of the hypothalamus 
or pituitary could explain some of the frequent symptoms in 
FM involving sleep pathology,57,58 fatigue,57 and cognitive 
complaints,58,59 as all have been related to hypothalamic 
or pituitary dysfunction or the downstream effects of such 
dysfunction.
The increased amount of gynecologic pathology in FM, 
as well as the relationship between the timing of gynecologic 
surgery and pain onset, indicates that a hypoestronergic 
state may contribute to increased pain perception. Despite 
striking sex differences in the prevalence of FM and other 
CP conditions, the effects of estrogen on pain perception are 
poorly understood. A relatively recent review of estrogen and 
pain highlighted the effects of estrogen on multiple sites and 
systems involved in nociceptive processing, including the 
hypothalamus, pituitary gland, descending noxious inhibitory 
controls, sympathetic nervous system, primary afferents, and 
the dorsal horn of the spinal cord.60 Estrogen has also been 
shown to modulate the capsaicin (TRPV1) receptor61,62 and 
the dorsal root ganglia.63 Data on the peak prevalence of 
FM approximately overlap with menopause, with one study 
showing a significant increase in prevalence in women after 
the age of 50 years,1 and a second study showing a peak 
prevalence between 55 and 64 years.64 Thus, further study of 
the relationship between estrogen and FM is warranted.
The primary limitation of the study is the limited stan-
dardization of the manner in which data were collected in 
the two separate pain clinics due to the study’s retrospective 
nature. In both clinics, the nursing staff take a medical his-
tory in a similar fashion; however, there is more of a focus 
on psychiatric comorbidity in the FM clinic. Consequently, 
the identified differences between the two groups may be an 
artifact of a lack of standardization in data collection methods, 
particularly with respect to psychiatric data. The most likely 
flaw would be an underrepresentation of psychiatric illness 
in one of the groups due to insufficient assessment. This is 
the reason that all data are presented in this paper with and 
without psychiatric data. It should be noted that the rates of 
depression found in the participants are generally consistent 
with a recent study of comorbidities in FM,9 which lends 
greater credence to the psychiatric data presented in the paper. 
Additionally, while both clinics diagnosed FM based on the 
American College of Rheumatology criteria from 1990 that 
uses tender points as a means of making a diagnosis, the tender 
point method is not an ideal means of diagnosing FM and has 
thus been replaced in more recent proposed guidelines.65 An 
additional limitation is that it was often difficult to find the 
desired information. For instance, the data related to the timing 
of surgery in relation to pain onset could only be identified 
in approximately half of the patients. Further, information 
related to hysterectomy was limited, such that it was impos-
sible to determine if ovaries were conserved or removed. 
This lack of specific documentation occurred in both groups 
and thus likely did not introduce bias. Similarly, the use of 
patient reported pain onset is not an entirely reliable outcome 
measure. In the future, a prospective study with standardized 
data collection methods including detail as to the timing and 
nature of surgical procedures will allow for more thorough 
study of the issues raised in this paper.
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